rilmenidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
alpha-2 adrenoreceptor agonists 2381 54187-04-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rilmenidine
  • oxaminozoline
  • rilmenidene
  • rilmenidine phosphate
  • rilmenidine dihydrogen phosphate
Oxazole derivative that acts as an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION.
  • Molecular weight: 180.25
  • Formula: C10H16N2O
  • CLOGP: 1.42
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 33.62
  • ALOGS: -2.13
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.90 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 328.41 32.34 209 4071 263206 63221536
Lactic acidosis 236.70 32.34 91 4189 38196 63446546
Hyperkalaemia 137.90 32.34 69 4211 54134 63430608
Allergic reaction to excipient 100.39 32.34 18 4262 355 63484387
Hyponatraemia 87.29 32.34 67 4213 111833 63372909
Mixed liver injury 75.76 32.34 23 4257 4712 63480030
Isosthenuria 75.65 32.34 12 4268 108 63484634
Rhabdomyolysis 72.51 32.34 42 4238 43909 63440833
Pyelitis 68.28 32.34 12 4268 210 63484532
Bladder hypertrophy 67.34 32.34 12 4268 228 63484514
Toxic skin eruption 66.74 32.34 27 4253 12858 63471884
Electrocardiogram PR shortened 65.37 32.34 12 4268 271 63484471
Multiple organ dysfunction syndrome 62.62 32.34 42 4238 56710 63428032
Angioedema 54.12 32.34 36 4244 47929 63436813
Creatinine renal clearance increased 50.03 32.34 11 4269 628 63484114
Carbohydrate antigen 15-3 increased 45.85 32.34 12 4268 1436 63483306
Eye oedema 45.28 32.34 12 4268 1508 63483234
Primary hyperaldosteronism 44.86 32.34 7 4273 56 63484686
Carcinoembryonic antigen increased 43.50 32.34 12 4268 1753 63482989
Drug reaction with eosinophilia and systemic symptoms 42.08 32.34 27 4253 33809 63450933
Renin decreased 40.78 32.34 7 4273 106 63484636
Bradycardia 40.58 32.34 36 4244 73191 63411551
Prevertebral soft tissue swelling of cervical space 39.96 32.34 6 4274 36 63484706
Fall 39.91 32.34 84 4196 392250 63092492
Peripheral artery haematoma 39.55 32.34 6 4274 39 63484703
Ischaemic stroke 37.35 32.34 20 4260 17937 63466805
Myoclonus 36.77 32.34 19 4261 15849 63468893
Blood aldosterone increased 36.68 32.34 7 4273 196 63484546
Intestinal transit time abnormal 36.40 32.34 6 4274 70 63484672
Overdose 35.15 32.34 41 4239 115037 63369705
Hypotension 34.48 32.34 64 4216 272540 63212202
Psychomotor retardation 34.22 32.34 12 4268 3858 63480884
Hypochloraemia 33.17 32.34 10 4270 1999 63482743
Cholestasis 32.96 32.34 22 4258 29412 63455330
Breast cancer recurrent 32.87 32.34 12 4268 4329 63480413

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 161.71 27.39 146 2256 304842 34649687
Cerebral haematoma 63.28 27.39 20 2382 4595 34949934
Lactic acidosis 61.56 27.39 35 2367 34737 34919792
Hyperkalaemia 61.12 27.39 45 2357 69344 34885185
Necrotising oesophagitis 51.16 27.39 11 2391 555 34953974
Hypovolaemic shock 47.54 27.39 18 2384 7067 34947462
Hemiplegia 33.77 27.39 14 2388 6958 34947571
Product name confusion 29.60 27.39 5 2397 67 34954462
Tubulointerstitial nephritis 28.91 27.39 18 2384 21006 34933523
Hypokalaemia 28.67 27.39 27 2375 58187 34896342
Pemphigoid 27.71 27.39 13 2389 8653 34945876
Wrong strength 27.53 27.39 5 2397 104 34954425

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 432.06 25.35 353 6428 519051 79218556
Lactic acidosis 261.96 25.35 125 6656 70234 79667373
Hyperkalaemia 177.11 25.35 114 6667 114284 79623323
Allergic reaction to excipient 97.24 25.35 18 6763 334 79737273
Hyponatraemia 78.97 25.35 86 6695 177762 79559845
Isosthenuria 72.56 25.35 12 6769 111 79737496
Cerebral haematoma 62.41 25.35 24 6757 7918 79729689
Electrocardiogram PR shortened 61.30 25.35 12 6769 303 79737304
Pyelitis 60.28 25.35 12 6769 331 79737276
Mixed liver injury 56.35 25.35 22 6759 7556 79730051
Bladder hypertrophy 52.47 25.35 12 6769 647 79736960
Toxic skin eruption 52.05 25.35 29 6752 22264 79715343
Angioedema 50.84 25.35 46 6735 75989 79661618
Rhabdomyolysis 49.47 25.35 52 6729 103079 79634528
Hypovolaemic shock 49.21 25.35 23 6758 12253 79725354
Carbohydrate antigen 15-3 increased 45.53 25.35 12 6769 1167 79736440
Pemphigoid 44.38 25.35 23 6758 15292 79722315
Ischaemic stroke 43.84 25.35 30 6751 33101 79704506
Creatinine renal clearance increased 43.58 25.35 11 6770 902 79736705
Overdose 43.34 25.35 65 6716 184141 79553466
Hypokalaemia 43.04 25.35 57 6724 143983 79593624
Multiple organ dysfunction syndrome 42.93 25.35 52 6729 120194 79617413
Necrotising oesophagitis 41.41 25.35 11 6770 1102 79736505
Blood aldosterone increased 40.21 25.35 8 6773 220 79737387
Eye oedema 38.89 25.35 12 6769 2051 79735556
Prevertebral soft tissue swelling of cervical space 38.57 25.35 6 6775 36 79737571
Renin decreased 38.39 25.35 7 6774 119 79737488
Intracranial haematoma 38.38 25.35 10 6771 930 79736677
Carcinoembryonic antigen increased 38.08 25.35 12 6769 2197 79735410
Primary hyperaldosteronism 36.90 25.35 7 6774 149 79737458
Fall 36.22 25.35 107 6674 487522 79250085
Intestinal transit time abnormal 35.01 25.35 6 6775 70 79737537
Breast cancer recurrent 34.57 25.35 12 6769 2965 79734642
Hepatic cytolysis 34.54 25.35 24 6757 27127 79710480
Hemiplegia 33.69 25.35 19 6762 14920 79722687
Renal failure 32.58 25.35 60 6721 200908 79536699
Drug reaction with eosinophilia and systemic symptoms 31.87 25.35 33 6748 64211 79673396
Peripheral artery haematoma 31.75 25.35 6 6775 125 79737482
Hypotension 31.14 25.35 95 6686 440222 79297385
Drug interaction 30.70 25.35 91 6690 415092 79322515
Rash maculo-papular 29.99 25.35 30 6751 56048 79681559
Myoclonus 29.57 25.35 22 6759 27638 79709969
Intestinal haemorrhage 28.76 25.35 13 6768 6413 79731194
Hypochloraemia 28.67 25.35 10 6771 2505 79735102
Vascular resistance systemic 27.26 25.35 4 6777 15 79737592
Bradycardia 26.54 25.35 44 6737 135513 79602094
Blood pressure inadequately controlled 26.08 25.35 12 6769 6165 79731442
Psychomotor retardation 26.07 25.35 12 6769 6172 79731435

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC06 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR Ki 7.44 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 5.05 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.37 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 7.90 CHEMBL
Nischarin Membrane receptor Ki 7.23 CHEMBL
Nischarin Unclassified Ki 7.95 CHEMBL

External reference:

IDSource
D08482 KEGG_DRUG
85409-38-7 SECONDARY_CAS_RN
C0140591 UMLSCUI
CHEBI:8862 CHEBI
CHEMBL289480 ChEMBL_ID
DB11738 DRUGBANK_ID
D000077769 MESH_DESCRIPTOR_UI
68712 PUBCHEM_CID
5846 INN_ID
P67IM25ID8 UNII
236379 RXNORM
005772 NDDF
005773 NDDF
765332006 SNOMEDCT_US
765333001 SNOMEDCT_US

Pharmaceutical products:

None